

| | |
|--|-------------|
| Program Faculty | i |
| Sponsorship and CME Credit | ii |
| CME Activity Assessment and Evaluation | iii |
| Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference | |
| Michael B. Atkins, Marc S. Ernstoff, Robert A. Figlin, Keith T. Flaherty, Daniel J. George, William G. Kaelin, Jr., Eugene D. Kwon, Towia A. Libermann, W. Marston Linehan, David F. McDermott, Augusto C. Ochoa, Allan J. Pantuck, Brian I. Rini, Mark A. Rosen, Jeffrey A. Sosman, Vikas P. Sukhatme, Johannes W. Vieweg, Christopher G. Wood, and Laura King..... | 667s |
| Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics | |
| W. Marston Linehan, Peter A. Pinto, Ramaprasad Srinivasan, Maria Merino, Peter Choyke, Lynda Choyke, Jonathan Coleman, Jorge Toro, Gladys Glenn, Cathy Vocke, Bert Zbar, Laura S. Schmidt, Donald Bottaro, and Len Neckers..... | 671s |
| The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma | |
| William G. Kaelin, Jr..... | 680s |
| Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead | |
| Jon Jones and Towia A. Libermann..... | 685s |
| Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy? | |
| Allan J. Pantuck, Arie S. Belldegrun, and Robert A. Figlin..... | 693s |
| Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome | |
| Christopher G. Wood..... | 697s |
| Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials | |
| John S. Lam, Allan J. Pantuck, Arie S. Belldegrun, and Robert A. Figlin..... | 703s |
| Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy | |
| R. Houston Thompson, Haidong Dong, and Eugene D. Kwon..... | 709s |
| Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma | |
| David F. McDermott..... | 716s |
| Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma | |
| Augusto C. Ochoa, Arnold H. Zea, Claudia Hernandez, and Paulo C. Rodriguez..... | 721s |
| Reversal of Tumor-Mediated Immunosuppression | |
| Johannes Vieweg, Zhen Su, Philipp Dahm, and Sergei Kusmartsev..... | 727s |
| Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang | |
| Marc S. Ernstoff, Todd S. Crocenzi, John D. Seigne, Nancy A. Crosby, Bernard F. Cole, Jan L. Fisher, Jill C. Uhlenhake, Diane Mellinger, Cathy Foster, Conrad J. Farnham, Kathleen Mackay, Zbigniew M. Szczepiorkowski, Susan M. Webber, Alan R. Schned, Robert D. Harris, Richard J. Barth, Jr., John A. Heaney, and Randolph J. Noelle..... | 733s |
| Biologic Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma | |
| Brian I. Rini and W. Kimryn Rathmell..... | 741s |
| Sorafenib in Renal Cell Carcinoma | |
| Keith T. Flaherty..... | 747s |
| Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma | |
| Daniel J. George..... | 753s |

The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer

Daniel Cho, Sabina Signoretti, Meredith Regan, James W. Mier, and Michael B. Atkins758s

Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer

Jeffrey A. Sosman, Igor Puzanov, and Michael B. Atkins764s

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma

Mark A. Rosen and Mitchell D. Schnall770s

Biomarkers for Monitoring Antiangiogenic Therapy

Rupal S. Bhatt, Pankaj Seth, and Vikas P. Sukhatme777s